Type 2 Diabetes Trial, Recruiting (NCT03875625)

Type 2 Diabetes Trial, Recruiting NCT03875625 Sponsor: Chinese University of Hong Kong Condition: Type 2 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT03875625 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 2 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People with a Body Mass Index (BMI) between 25 and 30 (considered overweight)
People with a BMI of 30 or higher who also have metabolic syndrome (a cluster of conditions such as high blood pressure, high blood sugar, and abnormal cholesterol levels)
People with a BMI of 35 or higher (considered severely obese)

Who may not be able to join:

People who have other types of liver disease (apart from what is being studied in this trial)
People who are currently taking medications known to affect the amount of fat in the liver
People whose waist measurement is 150 cm (about 59 inches) or more
People who weigh 250 kg (about 551 pounds) or more
People who are unable to have an MRI scan for any medical reason (such as having a pacemaker or metal implants) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Winnie C Chu, MD, Chinese University of Hong Kong

Phone: (852) 3505 2299

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03875625

Sponsor: Chinese University of Hong Kong

Phase: Not Applicable

Status: Recruiting

Condition: Type 2 Diabetes

Trial contact: (852) 3505 2299

More information: https://clinicaltrials.gov/study/NCT03875625

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People with a Body Mass Index (BMI) between 25 and 30 (considered overweight)
People with a BMI of 30 or higher who also have metabolic syndrome (a cluster of conditions such as high blood pressure, high blood sugar, and abnormal cholesterol levels)
People with a BMI of 35 or higher (considered severely obese)

Who may not be able to join:

People who have other types of liver disease (apart from what is being studied in this trial)
People who are currently taking medications known to affect the amount of fat in the liver
People whose waist measurement is 150 cm (about 59 inches) or more
People who weigh 250 kg (about 551 pounds) or more
People who are unable to have an MRI scan for any medical reason (such as having a pacemaker or metal implants) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Chinese University of Hong Kong

Registry

ClinicalTrials.gov

Start date

1 April 2019

Est. completion

31 December 2025

Where this trial is recruiting

Hong Kong

Primary endpoints

Use of modified Dixon Magnetic Resonance Imaging method to measure the response of adipose tissue in different organs following life style modification program or Bariatric surgery; Use of modified Dixon Magnetic Resonance Imaging method to measure the response of adipose tissue in different organs following life style modification program or Bariatric surgery 2; Use of modified Dixon Magnetic Resonance Imaging method to measure the response of adipose tissue in different organs following life style modification program or Bariatric surgery- 3; Use of modified Dixon Magnetic Resonance Imaging...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov